Turning 73 changes the math on your retirement account. The IRS no longer lets your traditional IRA compound in peace.

SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Carol Burt will become Lead Director on November 15, 2026. She will succeed Ron Taylor, Resmed's current Lead Director, who is not standing for reelection at the company's 2026 Annual Meeting of Stockholders on November 18, 2026, and will retire after more than 21 years of service to the company.

Avalon Trust Co bought a new stake in ResMed Inc. (NYSE: RMD) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 87,722 shares of the medical equipment provider's stock, valued at approximately $17,095,000. ResMed makes up 1.1% of Avalon

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

ResMed NYSE: RMD reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, as demand for sleep devices and masks increased. Non-GAAP earnings per share rose 16% to $2.95, while the company expanded gross margin despite continued inflation in electronic components and freight.

Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.

Shares of ResMed dropped about 6% in morning trade on Friday after the medtech company forecast fiscal 2027 revenue below Wall ​Street expectations, impacted by suspended ventilator sales and cost pressures.

Revenue: Group revenue for Q4 FY2026 was $1.5 billion, a 9% headline increase and 8% growth on a constant currency basis.Non-GAAP Earnings Per Share: Increased

ResMed Inc. (RMD) Q4 2026 Earnings Call Transcript

ResMed (RMD) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.9 per share. This compares to earnings of $2.55 per share a year ago.